[go: up one dir, main page]

BRPI0519117A2 - composto, composiÇço farmacÊutica, mÉtodo para tratar neoplasmas suscetÍveis em um mamÍfero, e, uso de um composto - Google Patents

composto, composiÇço farmacÊutica, mÉtodo para tratar neoplasmas suscetÍveis em um mamÍfero, e, uso de um composto

Info

Publication number
BRPI0519117A2
BRPI0519117A2 BRPI0519117-3A BRPI0519117A BRPI0519117A2 BR PI0519117 A2 BRPI0519117 A2 BR PI0519117A2 BR PI0519117 A BRPI0519117 A BR PI0519117A BR PI0519117 A2 BRPI0519117 A2 BR PI0519117A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
mammal
susceptible neoplasms
treating susceptible
Prior art date
Application number
BRPI0519117-3A
Other languages
English (en)
Inventor
David Michael Bender
David Michael Remick
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of BRPI0519117A2 publication Critical patent/BRPI0519117A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

COMPOSTO, COMPOSIÇçO FARMACÊUTICA, MÉTODO PARA TRATAR NEOPLASMAS SUSCETÍVEIS EM UM MAMÍFERO, E, USO DE UM COMPOSTO. A presente invenção refere-se às novas pró-drogas de amida de geneitabina, às suas composições e aos seus métodos de uso.
BRPI0519117-3A 2004-12-17 2005-11-30 composto, composiÇço farmacÊutica, mÉtodo para tratar neoplasmas suscetÍveis em um mamÍfero, e, uso de um composto BRPI0519117A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63742204P 2004-12-17 2004-12-17
PCT/US2005/043125 WO2006065525A1 (en) 2004-12-17 2005-11-30 Amide prodrug of gemcitabine, compositions and use thereof

Publications (1)

Publication Number Publication Date
BRPI0519117A2 true BRPI0519117A2 (pt) 2008-12-23

Family

ID=36168678

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519117-3A BRPI0519117A2 (pt) 2004-12-17 2005-11-30 composto, composiÇço farmacÊutica, mÉtodo para tratar neoplasmas suscetÍveis em um mamÍfero, e, uso de um composto

Country Status (31)

Country Link
US (1) US7691827B2 (pt)
EP (1) EP1831237B1 (pt)
JP (1) JP5022911B2 (pt)
KR (1) KR100874052B1 (pt)
CN (1) CN101080417B (pt)
AR (1) AR055009A1 (pt)
AT (1) ATE405573T1 (pt)
AU (1) AU2005316922B2 (pt)
BR (1) BRPI0519117A2 (pt)
CA (1) CA2589850C (pt)
CY (1) CY1108447T1 (pt)
DE (1) DE602005009255D1 (pt)
DK (1) DK1831237T3 (pt)
EA (1) EA011868B1 (pt)
ES (1) ES2310860T3 (pt)
HR (1) HRP20080529T3 (pt)
IL (1) IL183666A (pt)
MA (1) MA29154B1 (pt)
MX (1) MX2007007228A (pt)
MY (1) MY143677A (pt)
NO (1) NO20073368L (pt)
NZ (1) NZ554732A (pt)
PE (1) PE20060771A1 (pt)
PL (1) PL1831237T3 (pt)
PT (1) PT1831237E (pt)
RS (1) RS50629B (pt)
SI (1) SI1831237T1 (pt)
TW (1) TWI326687B (pt)
UA (1) UA86119C2 (pt)
WO (1) WO2006065525A1 (pt)
ZA (1) ZA200705019B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101108407B1 (ko) * 2006-06-21 2012-01-30 일라이 릴리 앤드 캄파니 젬시타빈 아미드 전구약물의 결정 형태, 그의 조성물 및 용도
TWI436775B (zh) 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
CN101525361B (zh) 2009-04-21 2010-11-17 济南圣鲁金药物技术开发有限公司 基于吉西他滨结构的前药及其合成方法及应用
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
CN102432654A (zh) * 2011-09-26 2012-05-02 宋云龙 吉西他滨酰胺衍生物及其制备方法和用途
US9447137B2 (en) 2012-11-07 2016-09-20 Nucorion Pharmaceuticals, Inc. Substituted gemcitabine aryl amide analogs
JP6420247B2 (ja) 2012-11-13 2018-11-07 ボーイエン セラピューティクス，インコーポレイティド ゲムシタビンプロドラッグ及びその使用
US10059733B2 (en) 2014-03-03 2018-08-28 Nucorion Pharmaceuticals, Inc. Gemcitabine analogs
WO2016078160A1 (zh) * 2014-11-17 2016-05-26 常州方圆制药有限公司 胞苷衍生物及其应用
US10435429B2 (en) 2017-10-03 2019-10-08 Nucorion Pharmaceuticals, Inc. 5-fluorouridine monophosphate cyclic triester compounds
CN117402189A (zh) 2018-01-10 2024-01-16 广东集宝医药技术有限公司 氨基磷(膦)酸缩醛和磷(膦)酸缩醛化合物
US11427550B2 (en) 2018-01-19 2022-08-30 Nucorion Pharmaceuticals, Inc. 5-fluorouracil compounds
CA3091027A1 (en) 2018-02-02 2019-08-08 Maverix Oncology, Inc. Small molecule drug conjugates of gemcitabine monophosphate
CN113166189A (zh) * 2018-04-26 2021-07-23 纳米医学控股有限公司 吉西他滨两亲性前体药物
CN108864250A (zh) * 2018-05-29 2018-11-23 北京大学 一种FAPα酶敏感的吉西他滨前体药物及其制备方法和应用
WO2020026054A1 (en) * 2018-08-03 2020-02-06 Cellix Bio Private Limited Compositions and methods for the treatment of cancer
US12110311B2 (en) 2019-07-17 2024-10-08 Nucorion Pharmaceuticals, Inc. Cyclic deoxyribonucleotide compounds
WO2021216427A1 (en) 2020-04-21 2021-10-28 Ligand Pharmaceuticals, Inc. Nucleotide prodrug compounds
PL442924A1 (pl) * 2022-11-23 2024-05-27 Politechnika Śląska Prolek - glikokoniugat pochodny gemcytabiny, jako związek o działaniu przeciwnowotworowym, sposób otrzymywania i zastosowanie

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526988A (en) * 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
US4965374A (en) * 1987-08-28 1990-10-23 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
YU43193A (sh) * 1992-06-22 1997-01-08 Eli Lilly And Company 2'-deoksi-2',2'-difluoro(4-supstituisani)pirimidinski nukleozidi antivirusnog i antikancerogenog dejstva i međuproizvodi
RU2131880C1 (ru) * 1992-06-22 1999-06-20 Эли Лилли Энд Компани Способ получения обогащенных бета-аномером нуклеозидов
GB2321454A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Gemcitabine esters and amides
HU224918B1 (en) 1997-01-24 2006-04-28 Conpharma As Gemcitabine derivatives, process for their preparation and pharmaceutical compositions containing them
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6624142B2 (en) * 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US6376470B1 (en) * 1999-09-23 2002-04-23 Enzon, Inc. Polymer conjugates of ara-C and ara-C derivatives
EP1567169A4 (en) 2002-11-04 2009-10-21 Xenoport Inc GEMCITABINE PROMOTERS, THEIR PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
US7846436B2 (en) * 2003-11-28 2010-12-07 Chemgenes Corporation Oligonucleotides and related compounds

Also Published As

Publication number Publication date
CY1108447T1 (el) 2014-04-09
HRP20080529T3 (en) 2008-12-31
MY143677A (en) 2011-06-30
AR055009A1 (es) 2007-08-01
WO2006065525A1 (en) 2006-06-22
CA2589850A1 (en) 2006-06-22
AU2005316922B2 (en) 2011-08-25
US20090156547A1 (en) 2009-06-18
IL183666A (en) 2011-09-27
UA86119C2 (ru) 2009-03-25
MX2007007228A (es) 2007-08-14
TWI326687B (en) 2010-07-01
KR20070086308A (ko) 2007-08-27
JP5022911B2 (ja) 2012-09-12
MA29154B1 (fr) 2008-01-02
CN101080417A (zh) 2007-11-28
NZ554732A (en) 2010-09-30
EP1831237B1 (en) 2008-08-20
DK1831237T3 (da) 2008-10-27
DE602005009255D1 (de) 2008-10-02
CN101080417B (zh) 2011-01-19
US7691827B2 (en) 2010-04-06
ATE405573T1 (de) 2008-09-15
EA200701300A1 (ru) 2007-10-26
EP1831237A1 (en) 2007-09-12
IL183666A0 (en) 2007-09-20
JP2008524218A (ja) 2008-07-10
TW200634023A (en) 2006-10-01
ES2310860T3 (es) 2009-01-16
PE20060771A1 (es) 2006-09-23
ZA200705019B (en) 2008-10-29
HK1109903A1 (en) 2008-06-27
CA2589850C (en) 2012-05-01
NO20073368L (no) 2007-07-16
RS50629B (sr) 2010-06-30
KR100874052B1 (ko) 2008-12-12
EA011868B1 (ru) 2009-06-30
PT1831237E (pt) 2008-09-22
AU2005316922A1 (en) 2006-06-22
PL1831237T3 (pl) 2009-01-30
SI1831237T1 (sl) 2009-02-28

Similar Documents

Publication Publication Date Title
BRPI0519117A2 (pt) composto, composiÇço farmacÊutica, mÉtodo para tratar neoplasmas suscetÍveis em um mamÍfero, e, uso de um composto
CR11623A (es) Compuestos
CO6450612A2 (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
BRPI0900711A2 (pt) compostos adequados para uso em tintas e tintas tendo tais compostos
NI201002092A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato.
DOP2007000018A (es) Moduladores de indol sulfonamida de receptores de progesterona
ECSP10010129A (es) Inhibidores de quinasas símil polo
MEP39508A (en) Antagonist anti-cd40 antibody pharmaceutical compositions
ECSP13013083A (es) Benzoxazepinonas fusionadas como moduladoras de canales iónicos
MX375715B (es) Profarmacos de metilfenidato, procesos de elaboración y uso de los mismos.
UA118673C2 (uk) Похідні 11-гідроксилу жовчних кислот та їх амінокислотні кон'югати як модулятори фарнезоїдного x-рецептора
UY32427A (es) Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
BR112013019211A2 (pt) amidas de piperidina espirocíclicas de pirrolopirazina como moduladores de canais de íon
BRPI0608604B8 (pt) moduladores de 2,3-dioxigenase de indolamina e composição farmacêutica
HN2006016313A (es) Derivados de amida sustituida y metodos de uso
EA201171216A1 (ru) Фенилацетат l-орнитина и способы его получения
BR112013033388A2 (pt) composição cimentícia e mistura
BR112014020826A2 (pt) moduladores e métodos de uso
BRPI0609741A8 (pt) composto, método de preparação e uso do mesmo, composição farmacêutica, e ,método para tratar distúrbios mentais em um mamífero.
CU20120021A7 (es) Derivados amido espirocíclicos
MX2015014336A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
MX2010002191A (es) Composiciones y metodos que emplean antagonistas nmda para lograr un efecto anestesico limitado.
UY31005A1 (es) Nuevos derivados de isoquinolinonas, procesos de preparacion, composiciones farmaceuticas conteniendolos y aplicaciones
EA200970042A1 (ru) Кристаллические формы пролекарства на основе амида гемцитабина, композиции на их основе и их применение
BRPI0607084A2 (pt) uso de um composto 11-desóxiprostaglandina, composição compreendendo o mesmo, e composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.